Cardiovascular recovery after kidney transplantation varies substantially, even early after surgery. We examined whether microbiota-derived uremic toxins, post-transplant gut microbiome profiles, and paired plasma metabolic changes were associated with blood pressure normalization and cardiac functional improvement at postoperative day 14. Among 624 kidney transplant recipients, blood pressure was measured before transplantation and at day 14, and plasma indoxyl sulfate and p-cresyl sulfate were quantified by LC–MS/MS at both time points. Early hypertension remission was predefined as mean systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg without antihypertensive medication at day 14; 468 recipients met these criteria, whereas 156 had persistent hypertension. Clinical phenotyping, echocardiography, paired plasma metabolomics, post-transplant gut metagenomics, bidirectional Mendelian randomization, mediation analysis, endothelial cell assays, and mouse fecal microbiota transplantation were integrated.Both toxins declined significantly by day 14, with larger reductions in the remission group. Greater toxin reductions were independently associated with blood pressure normalization and improved cardiac indices, including higher left ventricular ejection fraction, lower E/e′ ratio, and reduced NT-proBNP. The remission group also showed greater microbial diversity, enrichment of short-chain fatty acid-producing taxa such as Faecalibacterium, Roseburia, and Bifidobacterium, and lower abundance of aromatic amino acid-derived toxin pathways. Paired metabolomics demonstrated lower toxin-related metabolites and stronger butyrate- and propionate-associated signals. Mendelian randomization supported directional associations of genetically predicted indoxyl sulfate and p-cresyl sulfate with hypertension and heart failure, without evidence of reverse causality. In endothelial cells, these toxins increased oxidative stress and inflammation, reduced nitric oxide, and impaired angiogenesis; butyrate and remission-group serum partly reversed these effects. In mice, fecal microbiota transplantation from recipients with persistent hypertension transmitted blood pressure elevation, adverse metabolic signatures, and aortic endothelial injury, whereas butyrate attenuated these abnormalities.These findings identify a kidney–gut–metabolite–vascular axis associated with early cardiovascular improvement after kidney transplantation and support microbiota-derived toxin reduction and toxin-to-short-chain-fatty-acid balance as candidate biomarkers requiring external and long-term validation.